Wong TCL, Lee VHF, Law ALY, et al. - As no prospective data exist on stereotactic body radiation therapy (SBRT) as a bridge to liver transplantation for hepatocellular carcinoma (HCC), researchers herein investigated the efficacy and safety of SBRT as bridging therapy, with comparison with transarterial chemoembolization (TACE) and high intensity focused ultrasound (HIFU). They prospectively enrolled patients for SBRT under a standardized protocol, and compared them with a retrospective cohort of patients who underwent TACE or HIFU. Evaluation of overall 150 patients was done (SBRT n = 40, TACE n = 59, HIFU n = 51). Outcomes support the safety of undertaking SBRT, with achievement of significantly higher tumor control rate and reduced risk of waitlist dropout. Hence, they highlight its utility as an alternative to conventional bridging therapies.